Active Biotech AB Interim report January - September 2015

November 6, 2015 08:32 (CET)

LUND, Sweden, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Laquinimod

  • The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
  • The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned

Tasquinimod     

  • The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS

ISI          

  • Only commercial activities will be conducted from 2016

Financial summary

MSEK  July - Sept.   Jan. - Sept. Jan. - Dec.
 20152014 20152014 2014 
         
Net sales5.22.6 11.37.5 10.4 
         
Operating loss-22.2-55.7 -149.7-172.8 -228.5 
         
Loss for the period-23.4-56.6 -152.7-174.5 -231.5 
         
Loss per share, before and after dilution (SEK)-0.26-0.76 -1.70-2.33 -3.02 
         
Cash and cash equivalents (at the end of the period)    132.4161.0 328.5 

For further information, please contact:     

  Tomas Leanderson, 
  President and CEO
  Tel: +46 (0)46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

 

  The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January - September 2015 http://hugin.info/1002/R/1964749/717166.pdf

HUG#1964749